Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate

Journal of Lipid Research

Volumn 56, Issue 6, 2015, Pages 1134-1144

  Benesch, Matthew G K ^a   Zhao, Yuan Y ^a   Curtis, Jonathan M ^a   McMullen, Todd P W ^a   Brindley, David N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autotaxin inhibition; Cytokines; Fluorescent substrate 3 assay; Inflammation; Lysophosphatidylcholine

Indexed keywords

AUTOTAXIN; INTERLEUKIN 1BETA; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; CARBOLINE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHOLIPID; ONO-8430506; PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REGULATION; ENZYME RELEASE; ENZYME SYNTHESIS; FEEDBACK SYSTEM; FEMALE; IN VIVO STUDY; MELANOMA CELL LINE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE SUBSTRATE; THYROID CANCER CELL LINE; WOUND HEALING; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; CARBOLINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MICE; PHOSPHORIC DIESTER HYDROLASES; RECEPTORS, G-PROTEIN-COUPLED; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 84937143587     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M057661     Document Type: Article

References (58)

1. Benesch, M. G. K., Y. M. Ko, T. P. W. McMullen, and D. N. Brindley. 2014. Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions. FEBS Lett. 588: 2712-2727.
2. Brindley, D. N., F. T. Lin, and G. J. Tigyi. 2013. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim. Biophys. Acta. 1831: 74-85.
3. van Meeteren, L. A., P. Ruurs, C. Stortelers, P. Bouwman, M. A. van Rooijen, J. P. Pradere, T. R. Pettit, M. J. Wakelam, J. S. Saulnier-Blache, C. L. Mummery, et al. 2006. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26: 5015-5022.
4. Koike, S., K. Keino-Masu, and M. Masu. 2010. Deficiency of autotaxin/lysophospholipase D results in head cavity formation in mouse embryos through the LPA receptor-Rho-ROCK pathway. Biochem. Biophys. Res. Commun. 400: 66-71.
5. Koike, S., K. Keino-Masu, T. Ohto, F. Sugiyama, S. Takahashi, and M. Masu. 2009. Autotaxin/lysophospholipase D-mediated lysophosphatidic acid signaling is required to form distinctive large lysosomes in the visceral endoderm cells of the mouse yolk sac. J. Biol. Chem. 284: 33561-33570.
6. Koike, S., Y. Yutoh, K. Keino-Masu, S. Noji, M. Masu, and H. Ohuchi. 2011. Autotaxin is required for the cranial neural tube closure and establishment of the midbrain-hindbrain boundary during mouse development. Dev. Dyn. 240: 413-421.
7. Nikitopoulou, I., N. Oikonomou, E. Karouzakis, I. Sevastou, N. Nikolaidou-Katsaridou, Z. Zhao, V. Mersinias, M. Armaka, Y. Xu, M. Masu, et al. 2012. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J. Exp. Med. 209: 925-933.
8. Hozumi, H., R. Hokari, C. Kurihara, K. Narimatsu, H. Sato, S. Sato, T. Ueda, M. Higashiyama, Y. Okada, C. Watanabe, et al. 2013. Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Lab. Invest. 93: 508-519.
9. Benesch, M. G. K., X. Tang, T. Maeda, A. Ohhata, Y. Y. Zhao, B. P. C. Kok, J. Dewald, M. Hitt, J. M. Curtis, T. P. W. McMullen, et al. 2014. Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice. FASEB J. 28: 2655-2666.
10. Teo, K., and V. G. Brunton. 2014. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer. Biochem. J. 463: 157-165.
11. Euer, N., M. Schwirzke, V. Evtimova, H. Burtscher, M. Jarsch, D. Tarin, and U. H. Weidle. 2002. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus nonmetastatic cell lines. Anticancer Res. 22: 733-740.
12. Venkatraman, G., M. G. Benesch, X. Tang, J. Dewald, T. P. McMullen, and D. N. Brindley. 2015. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. FASEB J. 29: 772-785.
13. Tang, X., M. G. Benesch, J. Dewald, Y. Y. Zhao, N. Patwardhan, W. L. Santos, J. M. Curtis, T. P. McMullen, and D. N. Brindley. 2014. Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice. J. Lipid Res. 55: 2389-2400.
14. Tomsig, J. L., A. H. Snyder, E. V. Berdyshev, A. Skobeleva, C. Mataya, V. Natarajan, D. N. Brindley, and K. R. Lynch. 2009. Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. Biochem. J. 419: 611-618.
15. Albers, H. M., A. Dong, L. A. van Meeteren, D. A. Egan, M. Sunkara, E. W. van Tilburg, K. Schuurman, O. van Tellingen, A. J. Morris, S. S. Smyth, et al. 2010. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc. Natl. Acad. Sci. USA. 107: 7257-7262.
16. Kok, B. P., G. Venkatraman, D. Capatos, and D. N. Brindley. 2012. Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases. Chem. Rev. 112: 5121-5146.
17. Brindley, D. N., and C. Pilquil. 2009. Lipid phosphate phosphatases and signaling. J. Lipid Res. 50(Suppl): S225-S230.
18. van Meeteren, L. A., P. Ruurs, E. Christodoulou, J. W. Goding, H. Takakusa, K. Kikuchi, A. Perrakis, T. Nagano, and W. H. Moolenaar. 2005. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J. Biol. Chem. 280: 21155-21161.
19. Saunders, L. P., W. Cao, W. C. Chang, R. A. Albright, D. T. Braddock, and E. M. De La Cruz. 2011. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. J. Biol. Chem. 286: 30130-30141.
20. East, J. E., A. J. Kennedy, J. L. Tomsig, A. R. De Leon, K. R. Lynch, and T. L. Macdonald. 2010. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX). Bioorg. Med. Chem. Lett. 20: 7132-7136.
21. Cui, P., J. L. Tomsig, W. F. McCalmont, S. Lee, C. J. Becker, K. R. Lynch, and T. L. Macdonald. 2007. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg. Med. Chem. Lett. 17: 1634-1640.
22. Gendaszewska-Darmach, E., E. Laska, P. Rytczak, and A. Okruszek. 2012. The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin. Bioorg. Med. Chem. Lett. 22: 2698-2700.
23. Zhang, H., X. Xu, J. Gajewiak, R. Tsukahara, Y. Fujiwara, J. Liu, J. I. Fells, D. Perygin, A. L. Parrill, G. Tigyi, et al. 2009. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69: 5441-5449.
24. Nakanaga, K., K. Hama, and J. Aoki. 2010. Autotaxin-an LPA producing enzyme with diverse functions. J. Biochem. 148: 13-24.
25. Moolenaar, W. H., and A. Perrakis. 2011. Insights into autotaxin: how to produce and present a lipid mediator. Nat. Rev. Mol. Cell Biol. 12: 674-679.
26. Hooks, S. B., W. L. Santos, D. S. Im, C. E. Heise, T. L. Macdonald, and K. R. Lynch. 2001. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Biol. Chem. 276: 4611-4621.
27. Pilquil, C., J. Dewald, A. Cherney, I. Gorshkova, G. Tigyi, D. English, V. Natarajan, and D. N. Brindley. 2006. Lipid phosphate phosphatase-1 regulates lysophosphatidate-induced fibroblast migration by controlling phospholipase D2-dependent phosphatidate generation. J. Biol. Chem. 281: 38418-38429.
28. Morimoto, T., S. Nakatani, A. Ohhata, and T. Sugiyama, inventors; Ono Pharmaceuticals Co. Ltd., assignee. Tetrahydrocarboline derivative. World Patent WO2012005227 A1, Japanese. January 12, 2012.
29. Saga, H., A. Ohhata, A. Hayashi, M. Katoh, T. Maeda, H. Mizuno, Y. Takada, Y. Komichi, H. Ota, N. Matsumura, et al. 2014. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS ONE. 9: e93230.
30. Ferry, G., N. Moulharat, J. P. Pradere, P. Desos, A. Try, A. Genton, A. Giganti, M. Beucher-Gaudin, M. Lonchampt, M. Bertrand, et al. 2008. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J. Pharmacol. Exp. Ther. 327: 809-819.
31. Murata, J., H. Y. Lee, T. Clair, H. C. Krutzsch, A. A. Arestad, M. E. Sobel, L. A. Liotta, and M. L. Stracke. 1994. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269: 30479-30484.
32. Gaetano, C. G., N. Samadi, J. L. Tomsig, T. L. Macdonald, K. R. Lynch, and D. N. Brindley. 2009. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol. Carcinog. 48: 801-809.
33. Ferguson, C. G., C. S. Bigman, R. D. Richardson, L. A. van Meeteren, W. H. Moolenaar, and G. D. Prestwich. 2006. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org. Lett. 8: 2023-2026.
34. Ohta, H., K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, et al. 2003. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64: 994-1005.
35. Davis, M. D., J. J. Clemens, T. L. Macdonald, and K. R. Lynch. 2005. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280: 9833-9841.
36. Bolick, D. T., S. Srinivasan, K. W. Kim, M. E. Hatley, J. J. Clemens, A. Whetzel, N. Ferger, T. L. Macdonald, M. D. Davis, P. S. Tsao, et al. 2005. Sphingosine 1-phosphate prevents tumor necrosis factor-{alpha}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler. Thromb. Vasc. Biol. 25: 976-981.
37. Boucher, J., D. Quilliot, J. P. Praderes, M. F. Simon, S. Gres, C. Guigne, D. Prevot, G. Ferry, J. A. Boutin, C. Carpene, et al. 2005. Potential involvement of adipocyte insulin resistance in obesityassociated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia. 48: 569-577.
38. Dusaulcy, R., C. Rancoule, S. Gres, E. Wanecq, A. Colom, C. Guigne, L. A. van Meeteren, W. H. Moolenaar, P. Valet, and J. S. Saulnier-Blache. 2011. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J. Lipid Res. 52: 1247-1255.
39. Ferry, G., E. Tellier, A. Try, S. Gres, I. Naime, M. F. Simon, M. Rodriguez, J. Boucher, I. Tack, S. Gesta, et al. 2003. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278: 18162-18169.
40. Nishimura, S., M. Nagasaki, S. Okudaira, J. Aoki, T. Ohmori, R. Ohkawa, K. Nakamura, K. Igarashi, H. Yamashita, K. Eto, et al. 2014. ENPP2 contributes to adipose tissue expansion and insulin resistance in diet-induced obesity. Diabetes. 63: 4154-4164.
41. Cavalli, S., A. J. Houben, H. M. Albers, E. W. van Tilburg, A. de Ru, J. Aoki, P. van Veelen, W. H. Moolenaar, and H. Ovaa. 2010. Development of an activity-based probe for autotaxin. ChemBioChem. 11: 2311-2317.
42. Kawaguchi, M., T. Okabe, S. Okudaira, H. Nishimasu, R. Ishitani, H. Kojima, O. Nureki, J. Aoki, and T. Nagano. 2013. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem. Biol. 8: 1713-1721.
43. Gierse, J., A. Thorarensen, K. Beltey, E. Bradshaw-Pierce, L. Cortes-Burgos, T. Hall, A. Johnston, M. Murphy, O. Nemirovskiy, S. Ogawa, et al. 2010. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J. Pharmacol. Exp. Ther. 334: 310-317.
44. Nikitopoulou, I., E. Kaffe, I. Sevastou, I. Sirioti, M. Samiotaki, D. Madan, G. D. Prestwich, and V. Aidinis. 2013. A metabolicallystabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PLoS ONE. 8: e70941.
45. Nozaki, E., M. Gotoh, R. Tanaka, M. Kato, T. Suzuki, A. Nakazaki, H. Hotta, S. Kobayashi, and K. Murakami-Murofushi. 2012. Pharmaco logical evaluation of a novel cyclic phosphatidic acid derivative 3-S-cyclic phosphatidic acid (3-S-cPA). Bioorg. Med. Chem. 20: 3196-3201.
46. Nozaki, E., M. Gotoh, H. Hotta, S. Hanazawa, S. Kobayashi, and K. Murakami-Murofushi. 2011. Synthesis of enantiopure 2-carba-cyclic phosphatidic acid and effects of its chirality on biological functions. Biochim. Biophys. Acta. 1811: 271-277.
47. Lee, S. C., Y. Fujiwara, J. Liu, J. Yue, Y. Shimizu, D. D. Norman, Y. Wang, R. Tsukahara, E. Szabo, R. Patil, et al. 2015. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Mol. Cancer Res. 13: 174-185.
48. Xia, Q., A. M. Deng, S. S. Wu, and M. Zheng. 2011. Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis. Acta Pharmacol. Sin. 32: 1055-1062.
49. Stortelers, C., R. Kerkhoven, and W. H. Moolenaar. 2008. Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. BMC Genomics. 9: 387.
50. Fuerst, E., H. R. Foster, J. P. Ward, C. J. Corrigan, D. J. Cousins, and G. Woszczek. 2014. Sphingosine 1-phosphate induces pro-remodelling response in airway smooth muscle cells. Allergy. 69: 1531-1539.
51. Avery, K., S. Avery, J. Shepherd, P. R. Heath, and H. Moore. 2008. Sphingosine 1-phosphate mediates transcriptional regulation of key targets associated with survival, proliferation, and pluripotency in human embryonic stem cells. Stem Cells Dev. 17: 1195-1205.
52. Bennett, G., D. Sadlier, P. P. Doran, P. Macmathuna, and D. W. Murray. 2011. A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. BMC Cancer. 11: 50.
53. Murray, D., G. Horgan, P. Macmathuna, and P. Doran. 2008. NET1-mediated RhoA activation facilitates lysophosphatidic acid-induced cell migration and invasion in gastric cancer. Br. J. Cancer. 99: 1322-1329.
54. Tanaka, M., S. Okudaira, Y. Kishi, R. Ohkawa, S. Iseki, M. Ota, S. Noji, Y. Yatomi, J. Aoki, and H. Arai. 2006. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281: 25822-25830.
55. Brindley, D. N. 2004. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J. Cell. Biochem. 92: 900-912.
56. Dvorak, H. F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315: 1650-1659.
57. Scha¨fer, M., and S. Werner. 2008. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 9: 628-638.
58. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell. 144: 646-674.